With the new migraine drug Emgality (galcanezumab, Lilly) being applied reimbursement in Korea starting this month, a green light has been given to Teva-Handok’s new migraine drug as well.

The new drug has passed the reimbursement adequacy assessment of the Health Insurance Review and Assessment Service, after which the company will be entering pricing negotiations with the National Health Insurance Service.

The NHIS announced on the 1st that it decided that Teva’s Ajovy prefilled syringe and autoinjector (fremanezumab) were adequate for insurance reimbursement at the 9th Drug Reimbursement Evaluation Committee (DREC) meeting.

The drug, which is used for migraine prevention